Result for
Tag: treatment
April 12, 2021
Real-World Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States
[Pre-print, not peer-reviewed] Monoclonal antibody treatment significantly reduced the risk of subsequent emergency department visit or hospitalization among patients with COVID-19 (n = 598) in a real-world study using electronic health record data. Among 270 (45%) patients treated with the monoclonal antibody bamlanivimab, 5 (1.9%) presented to the emergency department (ED) or required hospitalization within…
Neutralization of SARS-CoV-2 Variants by Convalescent and Vaccinated Serum
[Pre-print, not peer-reviewed] Sera from convalescent individuals (n = 44) and individuals who received the Pfizer-BioNTech vaccine (n = 51) showed reduced neutralization activity against the SARS-CoV-2 B.1.1.7 and B.1.351 variants. Among vaccinated individuals, the geometric mean 50% receptor binding domain (RBD) antibody concentration was 1.3-fold lower for the B.1.1.7 variant and 1.4-fold lower for…
April 8, 2021
CERC-002 a Human Anti-LIGHT mAb Reduces Respiratory Failure and Death in Hospitalized COVID-19 ARDS Patients
[Pre-print, not peer-reviewed] The monoclonal antibody (mAb) treatment CERC-002 reduced mortality and the risk of respiratory failure through day 28 compared to placebo (84% vs 65%; p=0.044) among hospitalized COVID-19 patients with mild-to-moderate acute respiratory distress syndrome (ARDS) according to a randomized placebo-controlled study (n=83). Efficacy was highest among patients ≥60 years old (77% vs…
TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351)
[Pre-print, not peer-reviewed] Treatments for SARS-CoV-2 infection designed to inhibit SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2) and RNA-dependent RNA-polymerase (RdRp), proteins that play a role in cell entry, were shown to suppress in vitro viral replication of both variants of concern B.1.1.7 and B.1.351 with similar effectiveness as compared to the parent SARS-CoV-2 strain. Drug…
April 2, 2021
The Neutralization Potency of Anti-SARS-CoV-2 Therapeutic Human Monoclonal Antibodies Is Retained against Novel Viral Variants
[Pre-print, not peer-reviewed] Neutralizing activity of four experimental monoclonal antibodies (mAbs) (MD65, MD62, MD29 and BL6) targeting the receptor-binding domain (RBD) of SARS-CoV-2 were largely retained against a panel of the top 10 RBD mutations including mutations found in several variants of concern. Rosenfeld et al. (Apr 1, 2021). The Neutralization Potency of Anti-SARS-CoV-2 Therapeutic Human…
March 25, 2021
B.1.526 SARS-CoV-2 Variants Identified in New York City Are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
[Pre-print, not peer-reviewed] Neutralizing activity elicited by prior SARS-CoV-2 infection, mRNA vaccines (Pfizer-BioNTech and Moderna), or the Regeneron monoclonal antibody cocktail (REGN10933 and REGN10987) were similar against the B.1.526 variant with the S477N mutation compared to the widely circulating strain with the D614G mutation. In contrast, similar to other E484K harboring variants, the B.1.526 variant…
March 19, 2021
Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
A multicenter randomized open-labeled clinical trial found that adding Favipiravir to the treatment protocol for in patients with moderate to severe SARS-CoV-2 infection did not reduce the number of ICU admissions or intubations or In-hospital mortality compared to Lopinavir/Ritonavir regimen. It also did not shorten time to clinical recovery or length of hospital stay. Solaymani-Dodaran…
Interleukin-6 blocking agents for treating COVID-19: a living systematic review
A systematic review (10 randomized trials among 6896 people with COVID-19) found that treatment of COVID-19 patients with the IL-6 blocker tocilizumab reduces the risk of all-cause mortality over 28 days, compared standard of care (with or without placebo). On average, tocilizumab reduced the risk of death by 32 deaths per 1000 compared to standard…
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit
Intermediate-dose prophylactic anticoagulation treatment did not improve clinical outcomes among patients admitted to the ICU with COVID-19 compared with standard prophylactic anticoagulation, according to a randomized clinical trial (n=562). There was no difference in the primary composite outcome (an adjudicated venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or mortality within 30 days) between…
March 18, 2021
Mavrilimumab in Patients with Severe COVID-19 Pneumonia and Systemic Hyperinflammation (MASH-COVID): An Investigator Initiated, Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial
The monoclonal antibody treatment mavrilimumab did not significantly lower the proportion of patients with severe COVID-19 who were alive and off oxygen therapy at day 14 compared to placebo (52% vs 47%, OR = 1.48, 95% CI: 0.43-5.16) in a multicenter, double-blind placebo-controlled randomized trial (n=40). Patients were included in the study if they were…
Previous page Next page